GlassScriptPhysician profile
David K Yoon
NPI 1124023031
$20,283.20
in general payments reported to CMS, 2019-2025
36 companies · $4,233 in 2025
The $4,233 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,521 · 2020: $802 · 2021: $1,542 · 2022: $2,864 · 2023: $3,674 · 2024: $4,647 · 2025: $4,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,417.08 |
| Education | $137.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,093.76 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $1,774.91 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $1,715.19 | 2019-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,442.11 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $1,096.38 | 2022-2025 | |
| Celgene Corporation | $844.91 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $831.53 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $780.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $703.93 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| E.R. Squibb & Sons, L.L.C. | $623.61 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $584.71 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $559.90 | 2019-2024 | Stelara |
| Regeneron Healthcare Solutions, INC. | $514.82 | 2022-2025 | Dupixent |
| Pfizer INC. | $418.13 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $284.43 | 2024-2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $238.88 | 2024 | Dupixent |
| Daiichi Sankyo INC. | $227.17 | 2019-2020 | |
| Allergan, INC. | $226.70 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $218.88 | 2025 | Iqirvo |
| Organon LLC | $216.18 | 2022-2025 | Hadlima, Renflexis |
| Steris Corporation | $164.58 | 2025 | |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $84.81 | 2019-2021 | |
| Boston Scientific Corporation | $81.30 | 2021 | |
| Ironwood Pharmaceuticals, INC | $62.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.66 | 2023-2024 | Cyltezo |
| Qol Medical, LLC | $53.94 | 2024-2025 | Sucraid, Sucraid |
| Echosens North America, INC. | $43.45 | 2024-2025 | Fibroscan, Fibroscan |
| Vivus LLC | $37.22 | 2019 | |
| Dova Pharmaceuticals | $30.34 | 2019 | |
| Medtronic, INC. | $30.06 | 2022-2024 | Gi Genius |
| Mauna Kea Technologies, INC. | $26.95 | 2022 | |
| Intercept Pharmaceuticals, INC. | $26.89 | 2020-2023 | Ocaliva |
| Celltrion USA INC. | $23.10 | 2024 | Zymfentra |
| Merck Sharp & Dohme LLC | $18.39 | 2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.